Categories Analysis, Earnings, Health Care

Earnings preview Q4: Amyris likely to benefit from the new cannabinoid deal

Renewables product company Amyris (AMRS) is set to report its fourth quarter and full-year 2018 results on Monday, March 18 after the market closes. Analysts expect the company to report earnings of $0.44 per share on revenue of $98.52 million for the quarter ended December 31, 2018. On Friday, Amyris shares, which opened at $4.16 in the morning, closed down 5.3% at $3.93.

In the fourth quarter of 2017, the company reported GAAP loss of $0.17 per share and non-GAAP loss of $0.61 per share on revenue of $80.6 million. Amyris had projected 2018 revenue to be in the range of $185 million to $195 million.

Check out Amyris’ previous quarter earnings calls audios here

For the third quarter ended September 30, 2018, non-GAAP loss per share stood at 63 cents and GAAP loss per share was $1.67 on revenue of $14.9 million.

The Emeryville, California-based firm’s recent cannabis deal that is valued up to $255 million with a confidential partner is expected to boost the company’s bottom and top-line numbers. A final definitive agreement is expected by the end of March with commercialization of products expected within the next 18-24 months assuming appropriate regulatory approvals. Amyris stock surged 73% on this deal announcement.

The undisclosed partner is estimated to provide initially lab-based and later commercial scale milestone cash payments in tranches for the development and scaling of technology to produce CBD. In return, the partner will be granted a license to commercialize these products.

The recent boom in the US cannabis market is expected to positively impact Amyris’ performance in the future.

At December-end, Amyris signed a long-term agreement with Xinfu of China for a significant initial payment and a long-term minimum annual share of an existing nutritional product royalty arrangement. The company also received FDA’s acceptance for its zero-calorie sweetner in December 2018.

Canada-based marijuana giant Tilray (TLRY) is also expected to publish its quarterly earnings results on Monday after the market close.

Amyris stock had gained 18% so far this year, while it declined 4% in the past three months period.

 

Listen to on-demand earnings calls and hear how management responds to analysts’ questions

Most Popular

FDX Earnings: FedEx Q1 adjusted earnings drop; revenue up 5%

Cargo giant FedEx Corporation (NYSE: FDX) Thursday reported a decline in first-quarter adjusted earnings, despite an increase in revenues. The company also provided guidance for fiscal 2023. Net income, adjusted

Key highlights from Darden Restaurants (DRI) Q1 2023 earnings results

Darden Restaurants, Inc. (NYSE:DRI) reported first quarter 2023 earnings results. Total sales increased 6.1% year-over-year to $2.4 billion, driven by blended same-restaurant sales growth of 4.2%. Net earnings amounted to

ACN Earnings: Key quarterly highlights from Accenture’s Q4 2022 financial results

Accenture (NYSE: ACN) reported fourth quarter 2022 earnings results today. Total revenues were $15.4 billion, up 15% year-over-year in US dollars and up 22.4% in local currency. Net income attributable

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top